Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity by Emerich, Df et al.
Research Article
Widespread Striatal Delivery of GDNF from Encapsulated Cells
Prevents the Anatomical and Functional
Consequences of Excitotoxicity
Dwaine F. Emerich ,1 Jeffrey H. Kordower,2 Yaping Chu,2 Chris Thanos,3 Briannan Bintz,3
Giovanna Paolone ,4 and Lars U. Wahlberg1
1Gloriana Therapeutics, Providence, Rhode Island, USA
2Department of Neurological Sciences, Rush University Medical Center, Chicago Illinois, USA
3Cytosolv, Providence, Rhode Island, USA
4Department of Diagnostic and Public Health, Section of Pharmacology, University of Verona P.le, LA Scuro, Verona, Italy
Correspondence should be addressed to Dwaine F. Emerich; dfe@glorianatx.com
Received 9 November 2018; Accepted 11 February 2019; Published 11 March 2019
Guest Editor: Jolanta Dorszewska
Copyright © 2019 Dwaine F. Emerich et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Methods. Human ARPE-19 cells engineered to secrete high levels of the glial cell line-derived neurotrophic factor (GDNF) were
encapsulated into hollow ﬁber membranes. The devices were implanted into the rat striatum 1 week prior to striatal quinolinic
acid injections. Animals were evaluated using a battery of validated motor tests, and histology was performed to determine the
extent of GDNF diﬀusion and associated prevention of neuronal cell loss and behavioral deﬁcits. Results. Encapsulated
cell-based delivery of GDNF produced widespread distribution of GDNF throughout the entire implanted striatum.
Stereological estimates of striatal neuron number and volume of lesion size revealed that GDNF delivery resulted in near
complete neuroprotection. Conclusions. Delivery of neurotrophic molecules such as GDNF using encapsulated cells has reached
a technological point where clinical evaluation is justiﬁed. Because GDNF has been eﬀective in animal models of Parkinson’s
disease, stroke, epilepsy, and Huntington’s disease, among other debilitating neurodegenerative diseases, encapsulated cell-based
delivery of GDNF might represent one innovative means of slowing the neural degeneration seen in a myriad of currently
untreatable neurological diseases.
1. Introduction
Treating neurodegenerative diseases is an urgent challenge.
Neurotrophic factors are attractive therapeutic candidates
because they can enhance neuronal functioning, are neuro-
protective, and have the potential to reverse ongoing neuro-
degeneration that causes neurological deﬁcits. While
neurotrophic factors have been consistently eﬀective in ani-
mal models [1–8], clinical development and evaluation has
been limited. A major reason for the delayed development
of eﬀective neurotrophic therapies has been the inability to
deliver them across the blood-brain barrier (BBB) directly
to target sites in a stable, controlled, and continuous manner
[9–13]. Several strategies are under development to optimize
the diﬀusion and spread of trophic factors into the brain tis-
sue. These include direct brain infusion [14], various gene
therapy approaches [7, 8], cell therapies [15], and
biomaterial-based drug-delivery systems [15]. Each approach
has its own advantages and limitations, but none have yet
produced signiﬁcant enough eﬃcacy to justify widespread
clinical evaluation.
Here, we describe a novel means of delivering very high
concentrations of neurotrophic factors directly to the site of
neuronal damage using an encapsulated cell therapy technol-
ogy [16, 17]. Cells are enclosed in a semipermeable capsule,
which is then implanted into the brain. The capsule mem-
brane allows oxygen and nutrients to enter and nourish the
encapsulated cells while also allowing the therapeutic
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molecule of interest to leave the capsule and diﬀuse into the
surrounding brain tissue. Immunological reactions to the
encapsulated cells are reduced because the semipermeable
membrane prevents elements of the host immune system
from gaining access to the cells, thereby protecting against
rejection. Indeed, even under xenograft conditions, the cells
within the capsule remain viable without the need for
immunosuppression. Furthermore, using human cells as
the delivery vehicle further reduces the chances of immu-
nological reactions. The cell line was produced using a
transposon-based gene expression system resulting in high
protein secretion 1-2 orders of magnitude higher than that
used in previous cell encapsulation studies [18–20]. The cells
were encapsulated within devices containing an optimized
cell scaﬀolding previously shown to promote long-term cell
viability in both animal models [21, 22] and recent human
clinical trials in Alzheimer’s patients [23]. In this study, we
tested the hypothesis that encapsulated cell-based delivery
of the neurotrophic molecule glial cell line-derived neuro-
trophic factor (GDNF) could result in widespread, but tar-
geted, delivery of biologically active GDNF to the striatum.
GDNF-secreting devices were implanted into the rodent stri-
atum prior to quinolinic acid (QA) lesions. Comprehensive
histological analysis and neurological testing revealed that
GDNF was distributed throughout the striatum to exert a
potent, essentially complete, neuroprotective eﬀect. Together
with previous demonstrations of long-term, controlled, safe,
and targeted delivery of GDNF in small and large animal
models, these data provide ongoing support for continued
clinical development of this approach.
2. Methods and Materials
2.1. Subjects. Adult male Sprague-Dawley rats (Harlan
Laboratories), ∼3 months old and weighing 225-250 grams,
were housed in groups of 4 in a temperature- and
humidity-controlled colony room maintained on a 12-hour
light/dark cycle. Food and water were available ad libitum
throughout the experiment. All experimentation was con-
ducted in accord with National Institutes of Health guidelines.
2.2. Cell Culture. ARPE-19 cells were cultured using standard
plating and passaging procedures in T-175 ﬂasks with growth
medium; DMEM+glutamax (1x) was supplemented with
10% fetal bovine serum (Gibco). Routine culture consisted
of feeding the cells every 2-3 days and passaging them at
70-75% conﬂuence. Cells were incubated at 37°C, 90%
humidity, and 5% CO2.
2.3. Cell Line Establishment.Human GDNF cDNA optimized
for human cell line expression was produced by Invitrogen,
Denmark, and subsequently cloned to replace NGF in the
expression vector pT2.CAn.hNGF [21], resulting in the plas-
mid pT2.CAn.hoG. ARPE-19 cells were transfected with this
vector using the Sleeping Beauty (SB) transposon system as
previously described [21, 22]. Brieﬂy, cells were cotransfected
with the plasmid pT2.CAn.hoG and the SB vector
pCMV-SB-100x. As the SB vector does not contain a eukary-
otic selection marker cassette, it is only transiently expressed.
The transient expression window allows for the active,
transposase-mediated integration of the SB transposon, i.e.,
the inverted repeat SB substrate sequences and the sequences
contained within these repeats, including the GDNF expres-
sion and neomycin antibiotic resistance cassettes. Clones
were selected using G418 (Sigma-Aldrich, Copenhagen, Den-
mark), and single colonies were expanded and isolated based
on their GDNF release levels.
2.4. Device Fabrication. Cells were encapsulated into hollow
ﬁber membranes manufactured from 7mm segments of pol-
yethersulfone membrane (Akzo, Germany) internally ﬁtted
with ﬁlaments of polyethylene terephthalate yarn scaﬀolding
for cell adhesion. Prior to ﬁlling, cultured cells were dissoci-
ated and suspended in HE-SFM at a density of 8,333 cells/μl.
6μl of cell solution (5 × 104 cells in total) was injected into
each device using a custom-manufactured automated
cell-loading system. Devices were kept in HE-SFM at 37°C
and 5% CO2 for either 3 weeks (low-dose group) or 12 weeks
(high-dose group) prior to surgical implantation.
Previous studies [24] used scanning electron microscopy
(SEM) to examine the morphology of these membranes. SEM
cross sections of the polyethersulfone membrane conﬁrmed
that the membrane possessed a typical isoreticulated mor-
phology with a relatively dense, thin outer skin and an open,
much thicker macroporous substructure. Measures of mem-
brane cross sections revealed an inner diameter of 481μm, an
outer diameter of 663μm, and a corresponding wall thick-
ness of approximately 90μm.
2.5. Surgery. Rats were anesthetized with isoﬂurane (3-4%)
and placed into a stereotaxic instrument (Stoelting Inc.). A
midline incision was made in the scalp, and a hole drilled
for the unilateral placement of a device (7mm in length) into
the striatum using a stainless-steel cannula mounted to the
stereotaxic frame. The coordinates for implantation with
respect to the Bregma were as follows: AP: 0.0, ML: 3.2, and
DV: -7.5. After placement of the device, the cannula was
withdrawn and the skin sutured closed.
One week following device implantation, the rats were
anesthetized with isoﬂurane and positioned in a stereotaxic
frame for the injection of the QA (225nmol). A 28-gauge
Hamilton syringe was connected to the stereotaxic frame
and lowered into the previously implanted striatum at the
following coordinates with respect to the Bregma: AP: 1.0,
ML: 2.6, and DV: -5.0. The QA was infused in a volume of
1μl per site over 5 minutes. The needle was left in place for
an additional two minutes to allow the QA to diﬀuse from
the injection site then removed and the skin sutured closed.
The treated rats were allotted to 3 experimental groups: QA
lesion only (n = 8), QA+GDNF low-dose (n = 8), and QA
+GDNF high-dose (n = 6).
2.6. Neurological Evaluation. Using a validated battery of
tests [25], the rats were evaluated to provide a behavioral
measure of the extent of the lesion as well as the magnitude
of beneﬁt provided by the GDNF implants. All tests were
conducted 24 hours prior to device implantation (baseline),
24 hours prior to QA injection (prelesion), and again 2 and
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4 weeks postlesion. All testing was performed in a dim light
testing room and the individual tests included (in order of
testing) the following.
2.6.1. Cylinder Test of Spontaneous Forelimb Use. The rats
were placed individually in an acrylic cylinder (20 cm in
diameter and 40 cm in height), and left and right forepaw
contacts with the wall of the cylinder were quantiﬁed. Twenty
total forepaw contacts were required to complete each testing
session.
2.6.2. Spontaneous Forelimb Placing Use. The forelimb plac-
ing test assessed the rat’s ability to make directed forelimb
movements in response to sensory stimuli. The rats were held
with their limbs hanging unsupported and the length of their
body parallel to the edge of a table. They were then raised and
their whiskers were stimulated by brushing each side against
the edge of the table. In naïve rats, this elicits a same-side
forelimb response by placing the paw on the top of the table.
Each rat received 10 consecutive trials with each forelimb.
2.6.3. Stepping Test. Rats were placed on a ﬂat surface and
their hind legs gently lifted by raising their tail upward leav-
ing the forelimbs resting on the table surface. The animal was
pulled steadily backward, 1 meter over 30 seconds, and the
adjusting steps were recorded for each forepaw.
2.7. GDNF ELISA. GDNF secretion from cell-loaded devices
was conﬁrmed prior to implantation and again following
retrieval from the brain. Immediately following retrieval, all
devices were incubated at 37°C in HE-SFM. Media samples
(4-hour incubation) were collected the next day to quantify
GDNF release using a commercially available kit (DuoSet®
for human GDNF; R&D Systems, Minneapolis, MN).
2.8. Immunohistochemistry. Rats were deeply anesthetized
and transcardially perfused with 200ml of 0.9% ice-cold
saline. Following saline perfusion, the rats were decapitated
and the devices were removed and processed for GDF secre-
tion as described below. The brains were placed into Zambo-
ni’s ﬁxative for 1 week and then transferred to 25% sucrose
for 48 hours. Frozen, 40μm thick coronal sections through-
out the striatum and substantia nigra were cut and saved.
An immunoperoxidase labeling method was used to visualize
the volume of GDNF distribution in the rat striatum and sub-
stantia nigra while NewN-immunoreactive neurons were
assessed in the striatum only. Endogenous peroxidase was
quenched by 20-minute incubation in 0.1M sodium period-
ate, and background staining was blocked by 1-hour incuba-
tion in a solution containing either 2% bovine serum albumin
or 5% normal horse serum. Tissue sections were immuno-
stained for GDNF (R&D Systems, AF-212-NA; 1 : 500) and
NeuN (Millipore, MAB377; 1 : 1000) overnight at room tem-
perature. After 6 washes, the sections were sequentially incu-
bated for 1 hour in biotinylated horse anti-goat IgG (Vector
Laboratories; 1 : 200) for GDNF and horse anti-mouse IgG
(Vector Laboratories; 1 : 200) for NeuN followed by the Elite
avidin-biotin complex (Vector Laboratories; 1 : 500) for 75
minutes. The immunohistochemical reaction was completed
with 0.05% 3,3′-diaminobenzidine, 0.005% H2O2, and
0.05M nickel (II) sulfate. Sections were mounted on
gelatin-coated slides, dehydrated through graded alcohol,
cleared in xylene, and cover-slipped with Cytoseal (Richar-
d-Allan Scientiﬁc, Kalamazoo, MI).
2.9. Quantiﬁcation.Optical fractionator unbiased sampling was
used to estimate the total number of NeuN-immunoreactive
neurons within the striatum [26, 27]. In each rat, we evaluated
equispaced sections throughout the striatum length from its
most anterior extent (Bregma + 2 2 mm) to the caudal level
of the optic chiasm (Bregma − 1 3mm). The striatumwas out-
lined through a 1.25x objective using the Stereo Investigator
software (MicroBrightField, VT), and the total number of
NeuN-immunopositive neurons within the striatum was cal-
culated for each animal. The Cavalieri estimator [26–28] was
used to assess the volume of the striatum, the extent of QA
lesion, and the GDNF distribution. Serial coronal sections
extending throughout the striatum were sampled as described
above using a 100 × 100 μm point grid with a 10x objective.
The volume of the QA lesion was assessed by quantifying the
extent of the absent area, whereas GDNF distribution was
quantiﬁed by measuring the spreading of GDNF immunore-
activity, and the eﬀects of QA injections andGDNF treatments
on the striatal neural population were assessed by counting
NeuN-immunostained neurons. Quantiﬁcation of the relative
optical density (OD) of striatal GDNF immunoreactivity was
performed using an Olympus microscope coupled to a
computer-assisted morphometry system (Scion Image 1.63;
NIH), as described previously [27]. The GDNF immunostain-
ing throughout the striatum was identiﬁed and manually out-
lined. The OD was then automatically measured by using the
NIH image software. To account for diﬀerences in background
staining intensity, background ODmeasurements in each sec-
tion were taken from corpus callosum-lacking GDNF immu-
noreactive proﬁles and then subtracted from the OD of each
GDNF-stained striatum to provide a ﬁnal OD value.
3. Results
3.1. GDNF ELISA. GDNF secretion from cell-loaded devices
was conﬁrmed prior to implantation and again following
retrieval from the brain. In all animals, the implanted devices
were easily retrieved with no host tissue adhering to the cap-
sule wall, they were removed intact, and there was no evi-
dence that any capsule broke either in situ or during the
retrieval procedure. All implants were located centrally
within the striatum. Dorsally, the devices extended through
the corpus callosum, the overlying cortex, and extended ven-
trally to approximately the level of the anterior commissure.
Prior to implantation, device secretion corresponded to 163
± 5 0 ng/24 hours and 1056 ± 194 0 ng/24 hours for the
GDNF low- and GDNF high-dose groups, respectively. Fol-
lowing the 4-week implant, GDNF levels were elevated rela-
tive to preimplant values reaching secretion levels of
893 9 ± 205 6 ng/24 hours in the low-dose group and
2046 2 ± 381 0 ng/24 hours in the high-dose group.
3.2. Histology. Immunohistochemical staining of GDNF
secreted from encapsulated cells revealed robust distribution
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of the growth factor in all animals. Intense GDNF immuno-
reactivity was seen throughout the striatum and into the glo-
bus pallidus and ventral pallidum. Immunoreactivity was
also observed in the corpus callosum and the overlying cortex
adjacent to the implant site (Figure 1(a)). Neurons within the
pars compacta of the substantia nigra stained positive for
GDNF, consistent with the retrograde transport of the pro-
tein (Figure 1(c)). The volume of striatal GDNF was 10 99
± 1 1 mm3 for the low-dose group and 12 69 ± 1 24 mm3
for the high-dose group (Figure 1(b)). In these cases, the vol-
ume of GDNF distribution accounted for approximately 82%
and 90% of the total striatal volume, respectively. Quantita-
tive measures of the OD of GDNF staining conﬁrmed the
high levels of GDNF although no diﬀerences were noted
between the low- and high-dose GDNF groups (Figure 1(d)).
Immunohistochemical staining for NeuN conﬁrmed that
QA injections produced a marked spherical-shaped lesion
that encompassed much of the striatum at the level of the
injection (Figure 2(a)). Quantitative estimates of neuronal
numbers conﬁrmed both the magnitude of the QA lesion
and the robust neuroprotection induced by GDNF. While
neuronal numbers were decreased approximately 80% in
QA-lesioned animals, this loss was largely prevented by
GDNF with animals exhibiting a modest 15% and 6% neuro-
nal loss in the low- and high-dose GDNF groups, respectively
(Figure 2(b)). Lesion volume determinations showed a
similar pattern with large volumetric losses induced by QA
that were signiﬁcantly prevented by GDNF (Figure 2(c)).
QA injections produced a lesion that occupied approximately
65% of the total striatal volume. In contrast, treatment with
GDNF resulted in a robust neuroprotective eﬀect that mani-
fests as small lesions encompassing only 4-5% of the
implanted striatum (Figure 2(d)).
3.3. Behavioral Function. QA produced a signiﬁcant loss in
body weight that was attenuated by treatment with GDNF
(Figure 3). While nontreated animals lost >20% of their ini-
tial weight and did not begin to regain weight for approxi-
mately 1 week postlesion, the GDNF-treated animals
exhibited only a transient loss of weight lasting for approxi-
mately 24 hours that was then followed by a typical pattern
of weight gain thereafter. The loss in weight was attenuated
by both doses of GDNF, and this beneﬁt was slightly more
pronounced, but not statistically signiﬁcant, in the
high-dose group.
Tests of forelimb function in the cylinder, placing, and
stepping tests conﬁrmed that all groups of rats displayed nor-
mal forelimb use prior to the initiation of the study (preim-
plant; Figures 4(a)–4(c), respectively). Implantation of
GDNF devices did not impact performance on any of the
behavioral tasks. In contrast, the QA lesion produced signif-
icant behavioral deﬁcits in all 3 tests. This eﬀect was
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Figure 1:Widespread distribution of GDNF in the rat striatum. Photomicrographs of widespread GDNF immunoreactivity in the striatum of
rats implanted with the lower dose GDNF-secreting device (a) and associated immunoreactivity in the substantia nigra (c). Histograms of the
mean (±SEM) of the volume (b) and optical density (d) of GDNF staining. ∗p < 0 05.
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consistent and did not vary when the animals were tested at 2
versus 4 weeks postlesion. Relative to the intact forelimb, per-
formance on the contralateral, impaired forelimb was
decreased 69%-73%, 82%, and 49-56% (p’s < 0 05) in these
control animals on the cylinder, placing, and stepping tests,
respectively. In contrast, the GDNF-treated rats displayed a
notable, dose-related improvement in performance with the
higher dose of GDNF resulting in a virtually complete recov-
ery of behavior.
4. Discussion
Every year millions of people worldwide are diagnosed with a
neurodegenerative disorder that is ultimately fatal. Unfortu-
nately, despite signiﬁcant stepwise advances in our under-
standing of the underlying causes of many of these diseases,
eﬀective treatments have yet to be developed. This is particu-
larly true for treatments capable of slowing or even reversing
the insidious and progressive nature of many degenerative
diseases. Despite identifying trophic proteins that protect
and/or augment the function of targeted populations of neu-
rons in multiple animal models of human diseases, the dream
of translating preclinical success to the clinic has not yet been
realized.
While many factors play a role in the diﬃculty of trans-
lating preclinical work into an eﬀective therapy, an overrid-
ing issue across therapies is delivering proteins to the brain
at therapeutic levels. Direct brain delivery is usually required
due to the remarkably eﬀective protective physiology and
anatomy of the blood-brain barrier (BBB) that restricts entry
of the majority of systemically delivered molecules [29].
Attempting to bypass this barrier by directly injecting drugs
and proteins into the brain tissue also tends to be ineﬀective
because poor diﬀusion from a point source of infusion reduc-
ing exposure of the targeted tissue and limiting any therapeu-
tic impact [13]. These problems are compounded by the fact
that systemically delivered drugs, in particular proteins, are
large charged molecules that tend to be unstable and have a
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Figure 2: Protection of striatal neurons against QA toxicity. Photomicrographs of NeuN immunoreactivity illustrating an extensive loss of
striatal neurons (a) that is largely prevented by prior implantation with the lower dose GDNF-secreting device (c). Quantiﬁcation of
striatal neurons (b) conﬁrmed the extensive neuroprotection induced by GDNF with greater beneﬁts observed in those animals receiving
the higher dose implants. Quantiﬁcation of the striatal volume further illustrated both the extensive nature of the QA lesion and the
robust neuroprotection in GDNF-treated animals (d). ∗p < 0 05; ∗∗∗p < 0 001.
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high propensity to aggregate and misfold that renders them
ineﬀective and potentially toxic. Even if a protein can cross
the BBB, it will be widely distributed and mistargeted
throughout all brain parenchyma elevating the possibility
for serious side eﬀects such as those seen with mistargeting
of proteins including the glial cell line-derived neurotrophic
factor.
Here, we describe the use of polymer-encapsulated cells
as a platform technology approach that has matured over
the past 25 years and has now emerged as a viable therapeutic
option capable of providing targeted, long-term, continuous,
de novo synthesized delivery of very high levels of therapeu-
tic molecules that can be distributed over signiﬁcant portions
of the brain [30]. In this approach, cells are enclosed or
“encapsulated” within a capsule that has a semipermeable
outer wall or membrane that can be implanted directly into
the desired brain region [31–33]. The capsule wall morphol-
ogy can be controlled to provide a pore structure that allows
oxygen and nutrients to enter and nourish the cells while
simultaneously providing a route for cell-secreted proteins,
small molecules, antibodies, etc. to diﬀuse from the capsule
and into the adjacent brain tissue. Immunological reactions
that would typically occur against unencapsulated cells are
prevented because the same porous structure that permits
bidirectional ﬂow eliminates entry of damaging elements of
the host immune system into the capsule. Using
human-derived cells even further eliminates any potential
immunological reactions against the encapsulated cells. Of
note, the present study used 2 diﬀerent doses of GDNF
obtained by simply extending the duration that the encapsu-
lated cells were maintained in culture prior to implantation.
We chose this pragmatic method only as a means of demon-
strating a potential dose diﬀerence over the short duration of
this study recognizing that such an approach would be
insuﬃcient for longer term dose diﬀerentiation as the encap-
sulated cells would simply reach capacity and equilibrate.
Several more reliable and precise techniques of dose control
could be used in clinical development including modifying
the numbers of implants, changing the size of the devices
including both the diameter and length, obliterating the cen-
ter of the devices to alter the numbers of cells encapsulated,
or selecting clonal cell lines with diﬀerent secretion rates.
Intrastriatal injections of QA have been used as a model of
Huntington’s disease (HD) because the resulting excitotoxic
lesion produces morphological changes similar to those seen
in HD [34]. Trophic factors including GDNF and its family
member neurturin have shown promise in animal models of
several diﬀerent neurodegenerative disorders, including HD
[35–45]. The use of trophic factors has some unique appeal
as a potential therapeutic in HD because genetic testing
permits the identiﬁcation of mutated gene carriers destined
to suﬀer from HD [46]. Accordingly, identifying the genetic
marker provides the potential opportunity to intercede prior
to the development of symptoms secondary to neuronal
degeneration. Still, the acute onset of toxicity produced by
QA does not adequately capture the genetically driven onset
and progression of neurodegeneration seen in the human
disease, and the studies described here should be aug-
mented with data obtained from studies using genetic
mouse models of HD.
Ultimately, to be feasible, several essential prerequisites
would need to be satisﬁed to treat the chronic and progressive
nature of diseases such as HD. Here, we demonstrate that
encapsulated cell technology can be used to provide wide-
spread and targeted delivery of high levels of GDNF. These
studies are enabled by the development of cell lines produced
using a transposon-based gene expression system resulting in
high GDNF secretion together with optimized cell scaﬀolding
and membranes shown to promote long-term cell viability
in vivo [21–23]. Additional studies have shown that the
increases in striatal GDNF are persistent and stable for at least
6 months in the minipig putamen and 14 months in the rat
striatum (the longest time point examined). The widespread
GDNF diﬀusion was associated with pronounced behavioral
protection and preservation of striatal anatomy as measured
by sparing of NeuN-positive neurons and preservation of the
striatal volume.While encouraging, subsequent studies should
provide a more detailed analysis of striatal neuronal subtypes
including more precise indices of individual neuron morphol-
ogy and function. While not shown here, we have recently
published several papers in animal models [31, 32], including
excitotoxic lesions [33], that used GFAP immunohistochemis-
try to conﬁrm the lack of inﬂammatory response following
trophic factor delivery for longer periods of time than demon-
strated in the current studies. Immunohistochemistry was also
used to conﬁrm GDNF receptor engagement. GDNF signals
through a multicomponent receptor, ﬁrst binding the GDNF
family receptorα1 (GFRα1) with the resulting complex recruit-
ing the transmembrane receptor kinase Ret or the neural cell
adhesion molecule (NCAM) to initiate downstream signaling
pathways. We found that treatment with GDNF dramatically
increased the receptor expression and also highly increased
RET phosphorylation [32].
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Figure 3: GDNF prevents the loss in body weight following QA
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Formal, GLP-compliant safety/toxicology studies con-
ducted at Gloriana Therapeutics (unpublished data) have
also conﬁrmed the safety and tolerability of this approach
by demonstrating that minipigs receiving bilateral implants
of clinical-sized GDNF devices show no changes in food con-
sumption/weight gain or behavior, no changes in blood
chemistries, no production of anti-GDNF antibodies, and
no surgery- or GDNF-related histopathological alterations
were noted when the brains and peripheral organs were
examined by a board-certiﬁed neuropathologist.
In conclusion, the encapsulated cell-based delivery sys-
tem described here represents a greatly improved version of
previous encapsulated cell-based systems to deliver trophic
factors to the brain and to our knowledge is the ﬁrst cellular
delivery system capable of establishing the essential prerequi-
sites of sustained, targeted, long-term delivery of suﬃcient
quantities of GDNF to the CNS. As such, this approach rep-
resents a potentially novel and eﬀective treatment for HD
and other chronic neurodegenerative diseases.
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